Silence Therapeutics plc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
SLN$19.79+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Income (Loss)
(in thousands, except for loss per share)
| Year ended December 31, | |||||||
|---|---|---|---|---|---|---|---|
| Note · 2024 · 2023 · 2022 | |||||||
| Revenue | 3 | $43,258 | $31,643 | $21,655 | |||
| Cost of sales | (11,810) | (12,867) | (13,463) | ||||
| Gross profit | 31,448 | 18,776 | 8,192 | ||||
| Research and development costs | (67,883) | (56,937) | (43,550) | ||||
| General and administrative expenses | (26,884) | (26,222) | (25,682) | ||||
| Operating loss | (63,319) | (64,383) | (61,040) | ||||
| Foreign currency gain/(loss), net | 646 | (2,641) | 1,294 | ||||
| Other income, net | 6 | 4,472 | 1,803 | 280 | |||
| Benefit from R&D credit | 13,737 | 11,949 | 9,820 | ||||
| Loss before income tax expense | (44,464) | (53,272) | (49,646) | ||||
| Income tax expense | 17 | (845) | (956) | (688) | |||
| Net Loss | $(45,309) | $(54,228) | $(50,334) | ||||
| Loss per share (basic and diluted) | 7 | $(0.33) | $(0.49) | $(0.52) | |||
| Weighted average shares outstanding (basic and diluted) | 138,752,224 | 111,277,250 | 96,584,512 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.